Outcomes of intralesional interferon alpha-2B for the treatment of Peyronie's disease - Abstract

OBJECTIVES: To evaluate the efficacy of intralesional interferon alpha-2b (IFN) in Peyronie's Disease (PD), review the impact of timing of therapy from disease onset, and identify variables predictive of response.

METHODS: A retrospective chart review was performed of patients undergoing intralesional IFN from 2001-2012. Demographic information, disease characteristics, pre- and post-treatment penile duplex ultrasound (U/S) findings, and objective measures were analyzed. Response was defined as ≥20% improvement in curvature. Statistical analyses were performed to identify significant changes in variables and identify predictive factors.

RESULTS: A combined 127 patients with a mean age of 55 years (range 25-76) and mean pre-treatment curvature of 42.4 degrees (SD 18.6) underwent a median of 12, biweekly IFN injections (range 6-24). Median duration of PD was 2.0 years (range 0.5-23). Fifty-four percent of patients responded to therapy, with an overall mean improvement of 9.0 degrees (p< 0.001). Patients with curvatures < 30 degrees were most likely to experience a ≥20% improvement with IFN (86% response, p< 0.001); however, similar overall curvature improvements were noted among all pre-treatment curvatures. No statistically significant improvements were noted with penile vascular status or U/S parameters. Duration of PD did not impact change in curvature. Age, pretreatment curvature, vascular status, penile U/S findings, location of curvature, and International Index of Erectile Function score did not predict response to therapy.

CONCLUSIONS: Intralesional therapy with IFN results in significantly improved curvature without impact on penile vascular parameters. Absolute improvement in curvature is independent of pre-treatment curvature and duration of PD.

Written by:
Trost LW, Ates E, Powers M, Gur S, Sikka S, Hellstrom WJ.   Are you the author?
Tulane University, New Orleans, LA; Mayo Clinic, Rochester, MN.

Reference: J Urol. 2013 May 17. pii: S0022-5347(13)04358-9.
doi: 10.1016/j.juro.2013.05.022

PubMed Abstract
PMID: 23688848

UroToday.com Peyronie's Section